Articles | Volume 9, issue 3
https://doi.org/10.5194/jbji-9-167-2024
https://doi.org/10.5194/jbji-9-167-2024
Case report
 | 
13 Jun 2024
Case report |  | 13 Jun 2024

Ureaplasma urealyticum osteomyelitis of the greater trochanter in a patient with multiple sclerosis using ocrelizumab – a case report

Fred Ruythooren, Stijn Ghijselings, Melissa Depypere, Willem-Jan Metsemakers, Liesbet Henckaerts, Nathalie Noppe, and Georges Vles

Viewed

Total article views: 479 (including HTML, PDF, and XML)
HTML PDF XML Total BibTeX EndNote
386 70 23 479 12 13
  • HTML: 386
  • PDF: 70
  • XML: 23
  • Total: 479
  • BibTeX: 12
  • EndNote: 13
Views and downloads (calculated since 13 Jun 2024)
Cumulative views and downloads (calculated since 13 Jun 2024)

Viewed (geographical distribution)

Total article views: 448 (including HTML, PDF, and XML) Thereof 448 with geography defined and 0 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 

Cited

Latest update: 23 Nov 2024
Download
Short summary
The article examines a unique case of Ureaplasma urealyticum causing osteomyelitis in the greater trochanter of a 26-year-old male treated with ocrelizumab for multiple sclerosis. It emphasizes the necessity of a multidisciplinary approach and advanced PCR diagnostics to manage such rare opportunistic infections effectively, highlighting the challenges faced due to the immunosuppressive nature of monoclonal antibody therapies of this kind.